Abstract:Immunology is a truly international science which greatly benefits from the exchange and collaboration of scientists from different part of the world. The German Society for Immunology (Deutsche Gesellschaft für Immunologie, DGfI) maintains close connections with several national immunological societies to foster bilateral scientific interactions. Next to the initiation of joint meetings with the Japanese Society for Immunology (JSI), regular bilateral meetings with the Chinese Society for Immunology (CSI) is the oldest of those DGfI activities. Fortunately, the bilateral collaboration with the CSI has been generously supported from the beginning by the Sino-German Center for Research Promotion/Chinesisch-Deutsches Zentrum für Wissenschaftsförderung (SGC/CDZ) which is jointly funded and organized by the Deutsche Forschungsgemeinschaft (DFG) and the National Natural Science Foundation of Chinas (NSFC). The SGC is jointly led by a German and a Chinese director. As summarized by the new German director Dr. Karin Zach, the SGC offers various programs to support bilateral Chinese-German interactions in all fields of science. This includes sponsoring of Workshops and Mobility Programs, preparatory visits to initiate cooperations, Summer Schools, and others (see http://www.sinogermanscience.org.cn/). Several programs specifically support young scientists (advanced PhD students, post-doctoral researchers). Every year, about 30 excellent doctoral students nominated by Chinese universities can participate in the annual Lindau Nobel Laureate Meetings and spend additional time in German top research institutions and universities. Over the years (the program was initiated in 2004), a substantial number of them received a Lindau-follow up fellowship to conduct research in Germany. The series of bilateral DGfI-CSI workshops started in 2009 with the first meeting held at Burg Wanzleben near Magdeburg/Germany, organized by S. Meuer (Heidelberg). In fact, the first three meetings including the follow-up meetings 2011 in Beijing and 2013 at Kloster Eberbach/Germany were made possible on the basis of successful joint applications in the “Workshop” program of the SGC. Here, D. Kabelitz (Kiel) was the applicant from the German side, while X. Cao, W. He and B. Huang were the Chinese applicants in 2010, 2011 and 2013, respectively. Each of these workshops included a total of 30 immunologists, half of them from Germany and half from China. This initial workshop series served to get to know each other and to explore areas of common scientific interest. The unique ambience of the meeting venues and enjoyable social activities were added values which cannot be experienced at meetings with several hundreds or even thousands of participants. Inspired by the success of these bilateral workshops, D. Kabelitz (Germany) and X. Cao (China) submitted an application for a “Collaboration Group Tumor Immunology” to the SGC. The idea of this funding instrument was to intensify the bilateral interactions in a specific area of research. Following the discussions at the previous workshops, tumor immunology was identified as a suitable topic of great interest to basic and clinical immunologists in both countries, offering additional perspectives for clinical translation. The proposal was approved by the SGC, and the first meeting of the Cooperation Group took place in November 2015 in Chengdu/China. In addition to the applicants D. Kabelitz and X. Cao, the Cooperation Group comprised six members from the German side (S. Meuer, J. Wienands, C. Watzl, T. Kamradt, A. Radbruch, H.-M. Jäck) and four members from the Chinese side (Z. Tian, B. Huang, X. Quin, T. Chen). This notwithstanding, the SGC funds allowed to finance again the participation of a total of 30 delegates at four Meetings of the Collaboration Group. In addition, some funds were available to sponsor short laboratory visits. We continued to have the meetings alternating in Germany and in China. The second meeting took place in Dresden/Germany in December 2016 [1], the third meeting in Hangzhou/China in November 2017, and the final meeting of the Cooperation Group in March 2019 in Deidesheim/Germany. S. Meuer (Heidelberg) as the main organizer of the meetings in Germany selected wonderful places which offered unique opportunities for additional cultural and social activities, and the same was certainly true for the meetings in China. In the following we briefly highlight the presentations at the recent Deidesheim meeting which was attended by 18 immunologists from Germany and 16 from China (Figure 1). The first speaker was Xuetao Cao (Tianjin) who highlighted the crosstalk of epigenetic modifiers and innate molecules

Hepatologie trifft Infektiologie in Berlin

20 Jahre Hepatologischer Workshop in Iserlohn

Effekt des Screenings auf Hepatitis B und C im Rahmen des Check-Up 35 – Erste Erfahrungen einer großen hepatologischen Schwerpunktpraxis in Berlin

Infektiologie – eine neue Facharztdisziplin in Deutschland

Viszeralmedizin – Viszeralmedizin 2024

11. DNVF Forum Versorgungsforschung

S3-Leitlinie "Diagnostik und Therapie des Hepatozellulären Karzinoms" – Langversion 4.0

"Jeder trägt sein Licht ein Stück weit, dann gibt er es einem anderen"

Interprofessionelles Arbeiten

Lebertransplantation – Die deutschsprachige Leitlinie der DGVS und DGAV

Highlights der DDW 2021

S3-Leitlinie "Diagnostik und Therapie des Hepatozellulären Karzinoms" – Kurzversion

Successful hepatitis B and C screening in the health check-up in the German primary care setting

Themen – Ausschreibung zur Aktualisierung der S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome

Entzündlich-rheumatische Erkrankungen im Kontext von HIV, Hepatitis B und C

Report on the 2nd international molecular biosciences PhD and postdoc conference 2023: The emerging challenge – environmental impacts on human health

Chinese-German Cooperation Group Tumor Immunology: Another Inspiring Meeting in Deidesheim.

Gastroenterologie: Herausforderungen und Chancen für die Zukunft

XV. DGORh-Intensivmeeting in Kiel: Beitragsstrukturreform beschlossen

Neue Therapien, neue Herausforderungen – alte Bedürfnisse